Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Zelira Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $7.94 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 11.35 million
Earnings per share -3.236
Dividend per share N/A
Year To Date Return -18.89%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Zelira Therapeutics Ltd (ASX: ZLD)
    Latest News

    a woman
    ⏸️ Investing

    Pot stocks rocket: Here's what you need to know

    The Auscann Group Holdings Ltd (ASX:AC8) share price is one of five in the pot stock industry rocketing higher today…

    Read more »

    a woman
    ⏸️ Investing

    Why the Auscann Group Holdings Ltd share price just rocketed 15% higher

    The Auscann Group Holdings Ltd (ASX:AC8) share price has been one of the biggest movers on the market today. Here’s…

    Read more »

    a woman
    ⏸️ Investing

    ASX pot stock update: What you need to know

    From Auscann Group Holdings Ltd (ASX:AC8) to Zelda Therapeutics Ltd (ASX:ZLD), here’s what has been going on in the world…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares started the week with a bang

    The Avz Minerals Ltd (ASX:AVZ) share price is one of four starting the week strongly. Here’s what you need to…

    Read more »

    a woman
    ⏸️ Investing

    Why the AusCann share price rocketed higher today

    The Auscann Group Holdings Ltd (ASX:AC8) share price has rocketed 10.5% to 47 cents this morning. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    The Zelda Therapeutics Ltd share price is down 7%

    It hasn’t been a great day for the Zelda Therapeutics Ltd (ASX:ZLD) share price. It has fallen 7% today…

    Read more »

    a woman
    ⏸️ Investing

    ASX-listed pot stocks reviewed

    This portfolio of 14 pot stocks is up 278% since January 2017 but there are some big risks to be…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have climbed higher today

    The Bellamy's Australia Ltd (ASX:BAL) share price is one of four defying the market and climbing higher today. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why the Zelda Therapeutics Ltd share price rocketed 20% higher today

    The Zelda Therapeutics Ltd (ASX:ZLD) share price is up 20% today following a positive announcement. Here’s what you need to…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares are ending the week with a bang

    The Zelda Therapeutics Ltd (ASX:ZLD) share price is one of four shares finishing the week with strong gains. Here’s what…

    Read more »

    a woman
    ⏸️ Investing

    Why the Zelda Therapeutics Ltd share price rocketed 26% today

    The Zelda Therapeutics Ltd (ASX:ZLD) share price is having a strong finish to the week. Here’s why the pot stock…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have fallen lower today

    The Vita Group Limited (ASX:VTG) share price has continued to slide lower today. Here’s why it is one of four…

    Read more »

    ZLD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Zelira Therapeutics Ltd

    Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

    ZLD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    28 Mar 2024 $0.70 $-0.03 -4.11% 2,485 $0.73 $0.73 $0.70
    27 Mar 2024 $0.73 $0.01 1.39% 609 $0.72 $0.73 $0.72
    26 Mar 2024 $0.72 $0.02 2.86% 2,685 $0.70 $0.72 $0.70
    25 Mar 2024 $0.70 $0.01 1.45% 3,644 $0.70 $0.70 $0.70
    22 Mar 2024 $0.69 $-0.04 -5.52% 5,156 $0.70 $0.70 $0.69
    21 Mar 2024 $0.73 $0.03 4.29% 1,683 $0.70 $0.73 $0.70
    20 Mar 2024 $0.70 $0.01 1.45% 370 $0.69 $0.70 $0.69
    19 Mar 2024 $0.69 $0.00 0.00% 3,120 $0.69 $0.69 $0.69
    18 Mar 2024 $0.69 $-0.04 -5.48% 510 $0.72 $0.72 $0.69
    15 Mar 2024 $0.73 $-0.02 -2.67% 5,146 $0.74 $0.74 $0.69
    14 Mar 2024 $0.75 $0.00 0.00% 1,815 $0.75 $0.75 $0.75
    13 Mar 2024 $0.75 $0.00 0.00% 3,139 $0.75 $0.75 $0.75
    12 Mar 2024 $0.75 $0.00 0.00% 689 $0.75 $0.75 $0.75
    11 Mar 2024 $0.75 $0.06 8.63% 1,368 $0.75 $0.76 $0.75
    08 Mar 2024 $0.70 $0.01 1.45% 230 $0.70 $0.70 $0.70
    07 Mar 2024 $0.69 $-0.01 -1.43% 8,084 $0.69 $0.71 $0.69
    06 Mar 2024 $0.70 $-0.10 -12.50% 3,677 $0.81 $0.81 $0.70
    05 Mar 2024 $0.80 $-0.05 -5.88% 21,782 $0.85 $0.85 $0.80
    04 Mar 2024 $0.85 $0.00 0.00% 5,524 $0.85 $0.86 $0.85
    01 Mar 2024 $0.85 $0.00 0.00% 394 $0.85 $0.85 $0.85
    29 Feb 2024 $0.85 $0.00 0.00% 9,846 $0.91 $0.91 $0.85
    28 Feb 2024 $0.85 $0.00 0.00% 1,220 $0.85 $0.86 $0.85
    27 Feb 2024 $0.85 $0.00 0.00% 572 $0.85 $0.85 $0.85

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Nov 2023 Timothy (Tim) Slate Issued 100,000 $47,335
    Director remuneration.
    24 Nov 2023 Oludare Odumosu Issued 200,000 $94,669
    Director remuneration. As per announcement on 24-11-2023
    24 Nov 2023 Osagie Imasogie Issued 150,000 $71,002
    Director remuneration.
    24 Nov 2023 Greg Blake Issued 175,000 $82,836
    Director remuneration.
    24 Nov 2023 Donna O'Donnell Issued 145,000 $91,430
    Director remuneration.
    11 Sep 2023 Greg Blake Expiry 114,290 $113,147
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Timothy (Tim) Ryan Slate Company SecretaryNon-Executive Director Dec 2016
    Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
    Dr Oludare Odumosu Managing Director Dec 2019
    Dr Odumosu has over 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a combination of experiences from several academic, public health and life science organizations.
    Mr Osagie Imasogie Non-Executive ChairmanNon-Executive Director Dec 2019
    Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President.
    Mr Greg Blake Executive Director Feb 2023
    Mr Blake has led the strategic development and commercialization of several products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch pathway and commercialization planning for both domestic and international markets.
    Dr Donna Gentile O'Donnell Non-Executive Director Jun 2023
    Dr O'Donnell served as Special Assistant to the President, Dr. Stephen K Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organizations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years.

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr Malik Majeed 1,134,644 10.00%
    Quincy Street Capital Llc 456,622 4.02%
    Sharri J Rochlin <Rochlin Family Resource A/C> 393,168 3.46%
    Mr Zoltan Kerekes 393,168 3.46%
    Osagie Imasogie 393,168 3.47%
    Sunset Capital Management Pty Ltd <Sunset Superfund A/C> 383,725 3.38%
    Ms Lisa Gray 381,988 3.37%
    Mera I Llc\C 332,479 2.93%
    Mr Torsten M Geers <The Torsten M Geers Living A/C> 307,454 2.71%
    Mr Steve Shapiro 302,571 2.67%
    Mara Gordon 252,242 2.22%
    Ubs Nominees Pty Ltd 160,689 1.42%
    Mr Saul Shorr and Mrs Margaret Shorr 151,285 1.33%
    Dr Chanda Latrice Macias 146,479 1.29%
    Mera Ii Llc\C 133,372 1.18%
    Citicorp Nominees Pty Limited 132,506 1.17%
    Oludare Odumosu 131,766 1.16%
    Muller Ct Pty Ltd <Muller Super Fund A/C> 118,107 1.04%
    Mr Daniel Hexter and Mrs Shannon Hexter 103,389 0.91%
    Geers Egag Llc 85,715 0.76%

    Profile

    since

    Note